Sugi Predict

Sugi Predict / Compounds / Benznidazole

Benznidazole

Benznidazole

SCHEMBL17560897

O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1.O=[N+]([O-])n1ccnc1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.80
▸ CYP2D6 P10635 1/20 0.80
▸ OPRK1 P41145 1/20 0.80
▸ CA12 O43570 4/20 0.61
▸ CA1 P00915 4/20 0.61
▸ CA2 P00918 4/20 0.61
▸ CA9 Q16790 4/20 0.61
▸ LMNA P02545 3/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ THRB P10828 1/20 0.56
▸ KMT2A Q03164 3/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ MEN1 O00255 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ PKM P14618 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benznidazole SCHEMBL45081 0.89 CYP3A4 (1.00) CYP3A4CYP2D6OPRK1CA12CA1
Benznidazole SCHEMBL2324217 0.84 CYP3A4 (0.89) CYP3A4CYP2D6OPRK1CA12CA1
SCHEMBL29663426 0.79 CYP3A4 (0.78) CYP3A4CYP2D6OPRK1CA12CA1
Benznidazole SCHEMBL2329527 0.76 CYP3A4 (0.73) CYP3A4CYP2D6OPRK1CA12CA1
SCHEMBL15312866 0.76 CA2 (1.00) CYP3A4CYP2D6OPRK1CA12CA1
SCHEMBL15024639 0.75 LMNA (0.80) CYP3A4CYP2D6OPRK1CA12CA1
Etanidazole SCHEMBL4414 0.73 LMNA (1.00) CYP3A4CYP2D6OPRK1CA12CA1
Etanidazole SCHEMBL8171462 0.73 LMNA (1.00) CYP3A4CYP2D6OPRK1CA12CA1
SCHEMBL11946680 0.73 CYP3A4 (0.65) CYP3A4CYP2D6OPRK1LMNAKMT2A
Etanidazole SCHEMBL9473771 0.72 LMNA (0.97) CYP3A4CYP2D6OPRK1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566012-B2 Methods for treating protozoan infections NEOCULI PTY LTD (AU) 2023-01-31 — — US disclosed
EP-3188722-B1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2021-08-04 — — EP disclosed
CN-107106524-B Methods for treating protozoal infections 尼奥酷里私人有限公司 2021-06-01 — — CN disclosed
US-20210009552-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2021-01-14 — — US disclosed
US-10829468-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2020-11-10 — — US disclosed
US-20200290990-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2020-09-17 — — US disclosed
US-10752606-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2020-08-25 — — US disclosed
US-20200102287-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2020-04-02 — — US disclosed
US-10562880-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2020-02-18 — — US disclosed
US-20190330178-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2019-10-31 — — US disclosed
US-10392363-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2019-08-27 — — US disclosed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 — — US disclosed
CN-107106524-A Methods for treating protozoal infections 尼奥酷里私人有限公司 2017-08-29 — — CN disclosed
EP-3188722-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS Neoculi Pty Ltd (AU) 2017-07-12 — — EP disclosed
WO-2016033635-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2016-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566012-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-20200290990-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-20210009552-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-20200102287-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-20190330178-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-10829468-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-10562880-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-10752606-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885
US-10392363-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS CYP3A4 720/4885CYP2D6 569/4885OPRK1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.